Molecular Imaging Program National Cancer Institute 10 Center Dr Building 10, Room B3B69F Bethesda, MD 20892, USA.
Radiology. 2011 Jul;260(1):1-2. doi: 10.1148/radiol.11110740.
Mittra et al (1) describe a new positron emission tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropionyl labeled PEGylated dimeric RGD peptide (FPPRGD2), a marker of α(v)β(3) integrin expression, which they tested in fi ve healthy volunteers. No adverse events were encountered, and the biodistribution suggested both a renal and a hepatobiliary excretory route. This early safety testing paves the way for future studies of patients with cancer who are undergoing antiangiogenic therapies. (18)F-FPPRGD2 represents one of several integrin imaging agents that are moving closer to clinical reality.
米特拉等人(1)描述了一种新的正电子发射断层扫描(PET)放射性药物，氟 18((18)F)2-氟丙酰基标记的聚乙二醇化二聚体 RGD 肽(FPPRGD2)，这是 α(v)β(3)整联蛋白表达的标志物，他们在五名健康志愿者中进行了测试。未发生不良反应，其生物分布提示存在肾和肝胆排泄途径。这项早期安全性测试为正在接受抗血管生成治疗的癌症患者的进一步研究铺平了道路。(18)F-FPPRGD2 是几种正在接近临床现实的整合素成像剂之一。
